Role of PACAP in Prothrombotic State and Tubular Response in Congenital and Infantile Nephrotic Syndrome

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by Universitaire Ziekenhuizen Leuven.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Fund for Scientific Research, Flanders, Belgium
Information provided by:
Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier:
NCT01411982
First received: August 5, 2011
Last updated: NA
Last verified: December 2010
History: No changes posted

August 5, 2011
August 5, 2011
September 2011
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Role of PACAP in Prothrombotic State and Tubular Response in Congenital and Infantile Nephrotic Syndrome
Not Provided

This study will identify the role of PACAP (pituitary adenylate cyclase-activating polypeptide) deficiency in patients with nephrotic syndrome. PACAP is a neuropeptide that has a putative role as an inhibitor of megakaryopoiesis and platelet function. Additionally, some studies demonstrate its protective effect on the renal proximal tubule. Patients with nephrotic syndrome show decreased PACAP plasma levels, due to urinary loss. We hypothesize that in severe nephrotic syndrome, plasma deficiency of PACAP enhances megakaryopoiesis and causes blood platelet activation, which contribute to the increased rate of thromboembolic disease in these patients. Next, PACAP deficiency in peritubular capillaries might have a negative effect on proximal tubular function and enhance progression of the interstitial renal damage.

To test our hypothesis, we will address three main key-objectives. First, the role of PACAP deficiency on pro-thrombotic state in patients with nephrotic syndrome will be studied using patient blood and urine samples. Secondly, the influence of PACAP on the kidney in health and in nephrotic syndrome will be examined, using human renal cell lines and human kidney material. Finally, we will study the role of PACAP on pro-thrombotic state and renal disease progression in vivo, using selected animal models of nephrotic syndrome.

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Blood and urine

Non-Probability Sample

New patients with nephrotic syndrome of patients during a relapse of nephrotic syndrome.

Nephrotic Syndrome
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
35
Not Provided
Not Provided

Inclusion Criteria:

  • New patient with nephrotic syndrome of patient during relapse of nephrotic syndrome
  • Under 16 years old
  • Treatment for nephrotic syndrome not yet started by first sample collection

Exclusion Criteria:

  • None
Both
up to 18 Years
No
Contact: Benedicte Eneman, Med. Doctor 0032-16-347285 benedicte.eneman@uzleuven.be
Contact: Elena Levtchenko, Med. Doctor 0032-16-343827 elena.levtchenko@uzleuven.be
Belgium
 
NCT01411982
S52866
Not Provided
Benedicte Eneman, UZ Leuven
Universitaire Ziekenhuizen Leuven
Fund for Scientific Research, Flanders, Belgium
Not Provided
Universitaire Ziekenhuizen Leuven
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP